Roche: to present new data in MS
(CercleFinance.com) - Roche will present key new clinical and real-world data at ECTRIMS-ACTRIMS 2023, demonstrating robust long-term results in multiple sclerosis (MS), in addition to ENSPRYNG (satralizumab) for neuromyelitis optica spectrum disorder (NMOSD).
The latest results from the phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and the phase II trial of the BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented.
OCREVUS 10-year efficacy and safety data show a significant benefit in slowing the progression of long-term disability, and a consistent long-term safety profile in MS.
Longer-term safety data and late-breaking efficacy data from the Phase III trial of ENSPRYNG (satralizumab) in neuromyelitis optica spectrum disorder (NMOSD) will also be presented.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The latest results from the phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and the phase II trial of the BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented.
OCREVUS 10-year efficacy and safety data show a significant benefit in slowing the progression of long-term disability, and a consistent long-term safety profile in MS.
Longer-term safety data and late-breaking efficacy data from the Phase III trial of ENSPRYNG (satralizumab) in neuromyelitis optica spectrum disorder (NMOSD) will also be presented.
Copyright (c) 2023 CercleFinance.com. All rights reserved.